Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Association Found Between HS and Lymphoma

JAMA Dermatology; ePub 2019 Jan 30; Tannenbaum, et al

The chronic inflammatory state in hidradenitis suppurativa (HS) may result in development of clonal immune cell populations that give rise to malignant lymphomas. This according to a recent study that aimed to investigate prevalence of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and cutaneous T-cell lymphoma (CTCL) among patients with HS. This cross-sectional cohort analysis used standardized electronic health record information for 55 million patients from 27 integrated health systems across the US, limited to adults aged at least 18 years with active status between July 16, 2013, and July 16, 2018, who had complete information on sex and age. Researchers found:

  • 62,690 patients with HS were identified (25.6% men and 74.4% women).
  • Crude prevalences of NHL, HL, and CTCL among patients with HS compared with patients without HS (n=28,937,880) were 0.40% vs 0.35%, 0.17% vs 0.09%, and 0.06% vs 0.02%, respectively.
  • In multivariable analysis, patients with HS had increased overall odds of having NHL, HL, and CTCL.
  • Patients with HS appear to have 2 to 4 times the overall risk of developing lymphomas than that of the general population.
Citation:

Tannenbaum R, Strunk A, Garg A. Association between hidradenitis suppurativa and lymphoma. [Published online ahead of print January 30, 2019]. JAMA Dermatology. doi:10.1001/jamadermatol.2018.5230.